BREVAGen clinical sample for breast cancer sees progress
May 31, 2011
A new device developed by Genetic Technologies Limited is showing promise in its clinical sample trials. The BREVAGen breast cancer risk stratification test allows doctors to take a cheek swab sample from patients and look at their genetics to see if they have a high risk of breast cancer.
The company is hoping that this new technology enables better evaluation of patient risks, allowing for more accurate follow-ups for those who are at high risks of the disease.
"Sixty-four percent of the target patient population will have their breast cancer risk re-classified as a result of using the BREVAGen test, providing a more personalized and actionable assessment," said Lewis Stuart, Phenogen Sciences President and General Manager. "Many women will have their peace of mind improved by being re-classified to a lower risk group while for others, they will be re-classified to a higher risk group, enabling decisions regarding increased surveillance or even cancer preventive therapy."
More than 200,000 women are diagnosed with breast cancer each year in the U.S., according to the American Cancer Society. The rate amounts to about one in eight women who will have breast cancer at some point in her lifetime. Women over the age of 40 are recommended by the ACS to have yearly mammograms in order to catch tumors at their earliest onset.